BioMS Medical receives additional patent for multiple sclerosis drug MBP8298 in the United States

06-Nov-2006

BioMS Medical Corp announced that the University of Alberta has received additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive worldwide basis from the University of Alberta.

The most recent patent, entitled "Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient" has been granted in the United States and addresses methods of predicting efficacy of certain courses of treatment for MS patients.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances